高血清Lp-PLA2与帕金森病患者的认知障碍有关
Zubo Wu1, Defeng Shu2, Suyuan Wu3
1Department of Pediatrics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Frontiers in neuroscience
|March 27, 2024
概括
较高的脂蛋白相关脂酶A2 (Lp-PLA2) 水平与帕金森病 (PD-CI) 的认知障碍风险有关. 这种酶可以作为PD-CI的早期生物标志物,有助于早期检测和管理.
科学领域:
- 神经科学是一个神经科学.
- 生物化学 生物化学
- 临床神经学 临床神经学
背景情况:
- 帕金森病 (PD) 是一种神经退行性疾病.
- 认知障碍是PD患者常见的并发症.
- 脂蛋白相关脂酶A2 (Lp-PLA2) 是一种参与炎症过程的酶.
研究的目的:
- 研究Lp-PLA2水平与帕金森病 (PD-CI) 认知障碍风险之间的关联.
- 评估LP-PLA2作为PD-CI的潜在生物标志物.
主要方法:
- 对100名PD患者和60名健康对照进行了病例控制研究.
- 使用自动生化分析仪测量血清Lp-PLA2水平.
- 使用后勤回归和ROC曲线分析来评估LP-PLA2.2的关系和诊断价值.
主要成果:
- 与健康对照人群相比,PD患者的血清Lp-PLA2活性在正常认知 (PD-NC) 和PD-CI中显著升高.
- PD-CI患者的Lp-PLA2水平高于PD-NC患者.
- 较高的Lp-PLA2水平被确定为PD认知障碍的独立风险因素,预测AUC为0.659.
结论:
- 在PD患者中Lp-PLA2活性升高与认知障碍的风险增加有关.
- 血清Lp-PLA2可以作为一种方便和可访问的早期生物标志物,用于检测帕金森病中认知障碍.
- 监测Lp-PLA2水平可能有助于早期识别和管理PD-CI.
更多相关视频
07:26Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking
Published on: September 26, 2019
7.8K
07:08A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
Published on: October 20, 2016
7.8K
相关概念视频
Parkinson's Disease: Overview
541
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
541
Neural Regulation
39.4K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.4K
Parkinson's Disease: Treatment
264
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
264
Alzheimer's Disease: Overview
469
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
469
Lysosomal Hydrolases
3.8K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.8K
